{"title":"青少年特发性关节炎的无药无活动性疾病可达到40%的患者","authors":"L. Chapman, A. Friend","doi":"10.1136/archdischild-2019-317833","DOIUrl":null,"url":null,"abstract":"Study design : randomised, single-blind trial.\n\nSetting: The Netherlands.1 \n\nPatients: 94 patients with new-onset (symptom duration <18 months) juvenile idiopathic arthritis (JIA) who had not been exposed to previous disease-modifying antirheumatic drug (DMARD) therapy.\n\nInterventions: conventional systemic DMARD monotherapy (methotrexate (MTX) or sulfasalazine) versus MTX plus 6-week tapered course of prednisolone vs MTX plus etarnercept.\n\nOutcomes: time to inactive disease; time to flare after the first episode of drug-free inactive disease (DFID).\n\nMain results: …","PeriodicalId":8153,"journal":{"name":"Archives of Disease in Childhood: Education & Practice Edition","volume":"49 1","pages":"64 - 64"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug-free inactive disease in juvenile idiopathic arthritis can be achieved for 40% of patients\",\"authors\":\"L. Chapman, A. Friend\",\"doi\":\"10.1136/archdischild-2019-317833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Study design : randomised, single-blind trial.\\n\\nSetting: The Netherlands.1 \\n\\nPatients: 94 patients with new-onset (symptom duration <18 months) juvenile idiopathic arthritis (JIA) who had not been exposed to previous disease-modifying antirheumatic drug (DMARD) therapy.\\n\\nInterventions: conventional systemic DMARD monotherapy (methotrexate (MTX) or sulfasalazine) versus MTX plus 6-week tapered course of prednisolone vs MTX plus etarnercept.\\n\\nOutcomes: time to inactive disease; time to flare after the first episode of drug-free inactive disease (DFID).\\n\\nMain results: …\",\"PeriodicalId\":8153,\"journal\":{\"name\":\"Archives of Disease in Childhood: Education & Practice Edition\",\"volume\":\"49 1\",\"pages\":\"64 - 64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Disease in Childhood: Education & Practice Edition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/archdischild-2019-317833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Disease in Childhood: Education & Practice Edition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/archdischild-2019-317833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Drug-free inactive disease in juvenile idiopathic arthritis can be achieved for 40% of patients
Study design : randomised, single-blind trial.
Setting: The Netherlands.1
Patients: 94 patients with new-onset (symptom duration <18 months) juvenile idiopathic arthritis (JIA) who had not been exposed to previous disease-modifying antirheumatic drug (DMARD) therapy.
Interventions: conventional systemic DMARD monotherapy (methotrexate (MTX) or sulfasalazine) versus MTX plus 6-week tapered course of prednisolone vs MTX plus etarnercept.
Outcomes: time to inactive disease; time to flare after the first episode of drug-free inactive disease (DFID).
Main results: …
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
